

8 June 2014

ASPREE is a most important study as evidence of aspirin's value in older people is urgently required.

It would not of course have received ethics approval if it was thought there is a significant danger to the participants from adverse effects of aspirin.

Aspirin is a hugely valuable drug for people with cardiovascular disease and although there is circumstantial evidence that it might be valuable for healthy older people as well, this needs proof.

There is a lot of evidence that people who participate in trials of any kind do better than the remainder of the community, presumably because of the careful monitoring that is part of any clinical trial.

Nevertheless, participation in any clinical trial is very much a personal decision and I know this will be respected by the ASPREE team.

Garry Jennings

Professor Garry Jennings

Director

Baker IDI Heart and Diabetes Institute

75 Commercial Road, Melbourne VIC 3004

T [+61 \(0\)3 8532 1164](tel:+61(0)385321164) F [+61 \(0\)3 8532 1160](tel:+61(0)385321160)

E garry.jennings@bakeridi.edu.au

W www.bakeridi.edu.au

